hepat
c
viru
hcv
infect
associ
alter
host
lipid
insulin
signal
cascad
partial
explain
depend
hcv
life
cycl
key
molecul
metabol
pathway
yet
littl
known
role
hcv
life
cycl
glycogen
synthas
kinas
one
import
kinas
cellular
metabol
therefor
impact
hcv
life
cycl
assess
human
hepatoma
cell
line
harbor
subgenom
genotyp
replicon
produc
cell
culturederiv
hcv
genotyp
exposur
synthet
inhibitor
gene
silenc
overexpress
construct
immunofluoresc
analys
addit
role
hepat
e
viru
hev
replic
investig
assess
viru
specif
observ
find
found
inhibit
function
synthet
inhibitor
well
silenc
gene
express
result
decreas
hcv
replic
infecti
particl
product
wherea
silenc
isoform
relev
effect
hcv
life
cycl
convers
overexpress
result
enhanc
hcv
replic
contrast
effect
replic
subgenom
hev
replicon
provir
effect
hcv
replic
mediat
support
express
microrna
mandatori
wildtyp
hcv
replic
inhibitor
suppress
level
inhibitor
antivir
effect
hcv
mutant
conclus
identifi
novel
host
factor
support
hcv
replic
maintain
high
level
hepat
express
hepat
c
viru
member
flavivirida
famili
positivesens
singlestrand
rna
genom
lang
et
al
hcv
genom
encod
viral
structur
nonstructur
protein
requir
hcv
life
cycl
lang
et
al
addit
hcv
protein
number
host
factor
discov
hcv
critic
depend
lang
et
al
though
host
factor
cellular
protein
liverspecif
microrna
identifi
mandatori
hcv
replic
least
partial
respons
hepatotrop
viru
lang
et
al
chronic
infect
hcv
major
caus
liver
cirrhosi
hepatocellular
carcinoma
also
associ
metabol
trait
includ
insulin
resist
dyslipidemia
kawaguchi
et
al
shintani
et
al
bose
et
al
effect
hcv
infect
glucos
metabol
clearli
document
vivo
vitro
benefit
alter
viru
remain
larg
unclear
petta
et
al
negro
although
insulin
resist
identifi
neg
predictor
outcom
interferonbas
therapi
et
al
dai
et
al
grasso
et
al
moucari
et
al
khattab
et
al
fattovich
et
al
gglycogen
synthas
kinas
serinethreonin
protein
kinas
exist
two
isoform
encod
two
differ
gene
approxim
substrat
propos
highlight
central
role
numer
cellular
process
prolifer
migrat
apoptosi
immun
modul
importantlyglucos
metabol
jope
et
al
note
substrat
overlap
partial
activ
modul
inhibitori
phosphoryl
ser
ser
upstream
kinas
phosphoryl
ntermin
tail
act
pseudosubstr
prevent
incom
substrat
enter
catalyt
center
cohen
frame
import
highlight
role
pathogenesi
relev
diseas
includ
diabet
cancer
inflamm
beurel
et
al
accordingli
sever
inhibitor
preclin
clinic
develop
exampl
treatment
alzheim
diseas
diabet
del
ser
et
al
loveston
et
al
note
also
identifi
host
factor
requir
replic
influenza
sar
virus
wu
et
al
et
al
yet
role
hcv
life
cycl
remain
character
view
close
relationship
hcv
infect
metabol
alter
present
studi
aim
investig
possibl
role
hcv
life
cycl
cell
cultur
subgenom
replicon
cell
culturederiv
hcv
plasmid
human
hepatoma
cell
line
provid
charl
rice
rockefel
univers
new
york
ny
cultur
dmem
life
technolog
carlsbad
ca
contain
heatinactiv
fc
hcv
subgenom
replicon
construct
aflii
strain
genotyp
blight
et
al
provid
charl
rice
fulllength
hcv
construct
viru
genotyp
pietschmann
et
al
provid
ralf
bartenschlag
univers
heidelberg
germani
hcv
viru
genotyp
fulllength
strain
resist
inhibit
provid
jen
bukh
univers
copenhagen
denmark
li
et
al
cell
electropor
vitro
transcrib
fulllength
hcv
rna
h
later
viru
infect
supernat
assess
foci
form
unit
ffu
determin
use
antihcv
core
monoclon
antibodi
mab
moradpour
et
al
describ
zhong
et
al
cell
line
harbor
hev
genotyp
replicon
deriv
strain
provid
suzann
u
emerson
nation
institut
health
md
use
previous
describ
dao
thi
et
al
sofosbuvir
alsachim
sa
illkirchgraffenstaden
franc
hcv
inhibitor
resolv
dmso
use
final
concentr
inhibitor
lithium
chlorid
licl
sigmaaldrich
st
loui
mo
unit
state
resolv
steril
water
dmso
respect
cytotox
assess
use
assay
sigmaaldrich
haemagglutinintag
wildtyp
plasmid
wt
gift
jim
woodgett
lunenfeldtanenbaum
research
institut
mount
sinai
hospit
toronto
canada
addgen
plasmid
et
al
transfect
construct
overexpress
perform
final
dna
concentr
use
xtremegen
hp
dna
transfect
reagent
roch
diagnost
mannheim
germani
immunoblot
perform
describ
previous
lang
et
al
antibodi
total
purchas
cell
signal
technolog
danver
unit
state
mous
mab
hcv
provid
charl
rice
lindenbach
mab
hcv
describ
earlier
moradpour
et
al
ecl
donkey
hrpconjug
antirabbit
hrpconjug
antimous
secondari
antibodi
ge
healthcar
littl
chalfont
unit
kingdom
santa
cruz
biotechnolog
dalla
tx
unit
state
respect
total
rna
extract
done
use
rneasi
mini
kit
mirneasi
mini
kit
mrna
microrna
respect
qiagen
hilden
germani
revers
transcript
mrna
microrna
perform
use
primescript
rt
reagent
kit
takara
bio
otsu
japan
taqman
microrna
revers
transcript
kit
appli
biosystem
foster
citi
ca
unit
state
respect
realtim
pcr
steponeplu
realtim
pcr
system
appli
biosystem
use
hcv
gapdh
experi
carri
use
taqman
gene
express
master
mix
appli
biosystem
microrna
taqman
univers
master
mix
ii
appli
biosystem
use
quantif
mirna
cdna
follow
primer
use
hcv
amplif
forward
revers
figur
inhibit
suppress
hcv
replic
confirm
inhibit
immunoblot
analysi
carri
total
ser
phosphoryl
glycogen
synthas
gs
eukaryot
initi
factor
treatment
cell
harbor
replicon
h
indic
b
suppress
subgenom
hcv
replic
inhibit
cell
harbor
replicon
treat
differ
concentr
h
hcv
rna
level
normal
gapdh
mrna
express
rel
untreat
cell
c
assess
inhibitor
cytotox
cytotox
assay
carri
cell
stimul
h
differ
concentr
seed
densiti
cell
per
well
plate
absorb
read
nm
treat
cell
compar
neg
control
cell
treat
dimethyl
sulfoxid
vehicl
data
present
mean
sem
six
independ
experi
asterisk
denot
statist
signific
differ
pvalu
pvalu
pvalu
frontier
microbiolog
wwwfrontiersinorg
figur
requir
hcv
replic
silenc
suppress
hcv
replic
cell
harbor
subgenom
replicon
left
panel
replic
fulllength
clone
transfect
sirna
sirna
sirna
h
hcv
rna
level
normal
gapdh
mrna
express
rel
untreat
cell
data
present
mean
sem
two
experi
perform
triplic
asterisk
denot
statist
signific
differ
pvalu
pvalu
pvalu
immunoblot
analysi
carri
confirm
gene
silenc
effici
hcv
assess
suppress
hcv
replic
protein
level
lower
panel
detect
load
control
signal
intens
normal
quantif
present
mean
sem
signal
intens
duplic
band
b
overexpress
promot
hcv
express
cell
harbor
replicon
transfect
plasmid
express
hatag
wildtyp
h
immunoblot
analysi
carri
confirm
transfect
effici
overexpress
confirm
visual
distinct
band
slightli
higher
molecular
weight
endogen
hcv
protein
detect
assess
hcv
replic
level
detect
load
control
signal
intens
normal
quantif
present
mean
sem
signal
intens
duplic
band
frontier
microbiolog
wwwfrontiersinorg
tactca
hcv
taqman
probe
taqman
gene
express
assay
contain
predesign
primer
taqman
probe
appli
biosystem
use
gapdh
predesign
primer
assay
id
respect
thermo
fisher
scientif
employ
hev
procedur
primer
previous
describ
dao
thi
et
al
result
calcul
use
ct
method
shown
fold
chang
compar
control
gene
silenc
perform
describ
previous
lang
et
al
use
predesign
sirna
life
technolog
singl
sirna
well
nontarget
control
sirna
transfect
final
concentr
nm
use
lipofectamin
rnaimax
life
technolog
highli
select
small
molecul
inhibitor
inhibit
competit
atp
atpbind
site
kinas
meijer
et
al
prove
efficaci
inhibit
immunoblot
analys
phosphoryl
glycogen
synthas
gs
phosphoryl
downstream
target
perform
shown
figur
upregul
phosphoryl
gs
downregul
expect
next
expos
cell
harbor
subgenom
replicon
strain
differ
concentr
h
quantifi
hcv
rna
pcr
shown
figur
treatment
led
inhibit
hcv
rna
replic
note
relev
effect
cell
viabil
observ
consequ
inhibit
assess
assay
figur
compar
result
observ
treatment
cell
harbor
subgenom
replicon
lithium
chlorid
anoth
inhibitor
beurel
et
al
figur
next
cell
electropor
fulllength
hcv
genotyp
rna
treat
h
assess
effect
inhibit
infecti
hcv
shown
figur
inhibit
result
profound
inhibit
replic
infecti
hcv
clone
well
particl
product
figur
assess
whether
isoform
requir
hcv
replic
silenc
gene
express
transfect
sirna
quantifi
hcv
rna
cell
harbor
hcv
subgenom
replicon
infecti
hcv
shown
figur
upper
panel
silenc
gene
express
result
substanti
decreas
hcv
rna
level
subgenom
replicon
fulllength
hcv
construct
wherea
silenc
gene
express
minor
effect
hcv
replic
compar
result
observ
second
set
sirna
direct
supplementari
figur
suppress
effect
gene
silenc
hcv
replic
confirm
protein
level
quantifi
hcv
protein
figur
lower
panel
furthermor
enhanc
effect
hcv
rna
replic
confirm
overexpress
function
construct
increas
hcv
rna
replic
figur
test
whether
provir
effect
specif
hcv
assess
impact
inhibit
replic
hev
anoth
hepatotrop
positivestrand
rna
viru
shown
figur
neither
silenc
gene
figur
provir
effect
limit
hcv
comparison
hev
effect
inhibit
hev
replic
cell
harbor
select
hev
replicon
construct
hev
strain
treat
h
transfect
sirna
silenc
gene
express
h
hev
rna
level
normal
gapdh
mrna
express
rel
neg
control
sirnatransfect
cell
data
present
mean
sem
two
experi
perform
triplic
compar
wilcoxon
whitney
utest
ns
signific
control
group
b
inhibit
effect
hcv
cell
pretreat
h
dimethyl
sulfoxid
dmso
sofosbuvir
sof
infect
either
viru
moi
treat
condit
h
harvest
hcv
rna
level
normal
gapdh
mrna
level
express
rel
dmsocontrol
data
present
mean
sem
two
experi
perform
six
sampl
c
inhibit
effect
hcv
infecti
particl
product
infect
determin
foci
form
unit
ffu
assay
cell
supernat
harvest
h
postinfect
rna
treat
either
sof
result
shown
infect
level
normal
control
sampl
cultur
presenc
dimethyl
sulfoxid
vehicl
experi
data
present
mean
sem
two
experi
perform
six
sampl
asterisk
denot
statist
signific
differ
pvalu
pvalu
pvalu
express
treatment
inhibitor
relev
effect
hev
rna
level
suggest
provir
effect
specif
hcv
given
wellknown
depend
hcv
jopl
et
al
jopl
et
al
machlin
et
al
regulatori
circuit
insulinlik
growth
factor
receptor
identifi
previous
zeng
et
al
assess
effect
inhibit
express
cell
harbor
subgenom
hcv
replicon
shown
figur
treatment
result
downregul
level
similar
magnitud
compar
hcv
replic
inhibit
valid
cell
transfect
hcv
fulllength
rna
latter
hcv
construct
replic
independ
treat
shown
figur
inhibit
replic
fulllength
hcv
genom
replic
depend
presenc
contrast
inhibitori
effect
replic
entri
particl
product
hcv
line
observ
product
infecti
viral
particl
strongli
inhibit
wherea
inhibitor
effect
infecti
particl
product
viru
figur
suggest
inhibit
mainli
impact
hcv
rna
replic
view
remark
associ
hcv
metabol
trait
investig
role
hcv
life
cycl
key
kinas
glucos
metabol
numer
cellular
process
studi
show
serv
import
host
factor
viral
rna
replic
provir
effect
appear
mediat
least
part
maintain
hepatocellular
level
key
microrna
import
microrna
predominantli
express
hepatocyt
account
approxim
entir
microrna
pool
high
abund
liver
cell
underlin
key
function
liver
develop
growth
differenti
homeostasi
bandiera
et
al
surpris
therefor
repress
express
promot
develop
hepatocellular
carcinoma
hcc
addit
involv
import
metabol
function
liver
includ
cholesterol
fatti
acid
synthesi
iron
homeostasi
esau
et
al
castoldi
et
al
uniqu
featur
hcv
life
cycl
depend
presenc
stabil
hcv
genom
promot
viral
replic
bind
untransl
region
utr
viral
genom
jopl
et
al
jopl
et
al
machlin
et
al
given
liverspecif
express
microrna
also
consid
key
determin
hepatotrop
hcv
strong
depend
hcv
evidenc
profound
suppress
viral
load
therapeut
silenc
vivo
lanford
et
al
janssen
et
al
given
tumor
suppressor
function
therapeut
silenc
strategi
may
associ
increas
risk
hcc
develop
addit
recent
studi
shown
hcv
function
regul
sequest
within
hepatocyt
result
derepress
target
gene
presenc
hcv
may
partial
explain
oncogen
potenti
chronic
hepat
c
luna
et
al
find
specif
requir
maintain
level
hcv
infect
hepatocyt
add
anoth
facet
complex
reciproc
relationship
hcv
implic
chronic
hcv
infect
metabol
oncogen
trait
yet
limit
studi
complet
exclud
target
addit
involv
suppress
hcv
replic
inhibit
howev
appear
plausibl
deplet
play
key
role
mediat
suppress
hcv
replic
one
import
host
factor
hcv
replic
critic
depend
confirm
notion
import
find
hcv
mutant
resist
inhibit
addit
inhibit
suppress
effect
replic
hev
viru
contrast
hcv
depend
result
confirm
studi
zeng
et
al
describ
regulatori
circuit
insulinlik
growthfactor
receptor
hepatocyt
zeng
et
al
multifunct
protein
estim
differ
substrat
therebi
regul
numer
cellular
process
pathway
beyond
glucos
metabol
henc
inappropri
signal
appear
involv
divers
diseas
diabet
mellitu
cancer
diseas
though
number
inhibitor
preclin
clinic
develop
concern
seriou
side
effect
due
pleiotrop
effect
howev
signific
undesir
effect
inhibit
particular
accumul
potenti
deleteri
carcinogen
effect
develop
result
combin
inhibit
rayasam
et
al
regard
find
affect
level
import
may
serv
proofofprincipl
select
target
isoform
may
suitabl
approach
manipul
specif
function
data
illustr
need
dissect
role
isoform
separ
instead
nonspecif
refer
inhibit
view
pleiotrop
cellular
function
surpris
virus
engag
import
kinas
complet
life
cycl
shown
replic
sar
coronaviru
depend
phosphoryl
nucleocapsid
n
protein
necessari
process
viral
replic
wu
et
al
addit
shown
promot
life
cycl
influenza
viru
facilit
viral
entri
step
et
al
report
role
hcv
life
cycl
add
anoth
facet
depend
virus
central
kinas
furthermor
role
hcv
life
cycl
may
restrict
hcv
replic
recent
report
shown
support
hcv
assembl
involv
lipoprotein
product
sarhan
et
al
make
observ
experiment
set
data
indic
like
remain
margin
compar
role
support
hcv
rna
replic
yet
import
find
may
rather
consist
implic
understand
pathogenesi
chronic
hepat
c
identif
novel
target
antivir
therapi
downstream
target
insulin
inhibit
insulin
receptor
signal
welsh
proud
reciproc
inhibit
pivot
downstream
target
insulin
receptor
nonstimul
condit
glycogen
synthas
woodgett
cohen
roach
eldarfinkelman
kreb
liberman
eldarfinkelman
result
increas
activ
observ
diabet
tissu
eldarfinkelman
et
al
nikoulina
et
al
inhibit
activ
improv
insulin
resist
cline
et
al
henriksen
et
al
nikoulina
et
al
consequ
one
may
specul
depend
hcv
activ
could
explain
benefit
hcv
insulin
resist
induc
hepat
c
associ
lower
chanc
treatmentinduc
viral
clearanc
era
interferon
therapi
et
al
